Evidence map›Paper›PMID 31617061›Full record

SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2020

Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials.

G Roviello, M R Gatta Michelet, A D'Angelo, S Nobili, E Mini

Abstract readMeta-AnalysisReview
PubMed Publisher
In one paragraph

Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

G RovielloDepartment of Health Sciences, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy. giandomenicoroviello@hotmail.it.ORCID http://orcid.org/0000-0001-5504-8237
M R Gatta MicheletSchool of Human Health Sciences, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
A D'AngeloDepartment of Biology and Biochemistry, University of Bath, Bath, B2 7AY, UK.
S NobiliDepartment of Health Sciences, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy.
E MiniDepartment of Health Sciences, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNovel hormonal therapies have been recently investigated in non-metastatic castration-resistant prostate cancer (CRPC). We performed a meta-analysis to assess the efficacy and safety of novel hormonal therapies in non-metastatic CRPC. MATERIALS AND

methodsThe primary outcome was metastasis-free survival (MFS). The secondary endpoints were overall survival (OS), time to PSA progression and safety. We planned a subgroup analysis according to the PSA doubling time (> 6 vs < 6 months), Eastern Cooperative Oncology Group (ECOG) performance status (1 vs 0) and concomitant use of bone-targeting agent (yes vs no).

resultsPooled analysis of novel hormonal therapies revealed significantly increased MFS compared with placebo (hazard ratio (HR): HR = 0.32, 95% CI 0.25-0.41; p < 0.00001). The subgroup analysis showed a statistically significant MFS advantage in favour of men with the lower ECOG performance status. Other secondary endpoints favoured the novel hormonal therapies. The relative risk (RR) of grade ≥ 3 adverse events and ≥ 3 hypertension was 1.31 and 1.39, respectively.

conclusionsThis study confirmed the efficacy and safety of the novel hormonal therapies in non-metastatic CRPC.

Indexed as

Antineoplastic Agents, HormonalBenzamidesHumansMaleNitrilesPhenylthiohydantoinProgression-Free SurvivalProportional Hazards ModelsProstatic Neoplasms, Castration-ResistantPyrazolesRandomized Controlled Trials as TopicSurvival RateThiohydantoinsAntineoplastic Agents, HormonalapalutamideBenzamidesdarolutamideenzalutamideNitrilesPhenylthiohydantoinPyrazolesThiohydantoinsApalutamideDarolutamideEnzalutamideProstate cancer

Identifiers

PMID31617061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.